Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00328367 |
Recruitment Status
:
Completed
First Posted
: May 19, 2006
Last Update Posted
: October 29, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia | Drug: aripiprazole Drug: placebo | Phase 4 |
Clozapine is renowned for its efficacy in treating schizophrenia refractory to typical or atypical antipsychotics. Though the effectiveness of clozapine has been established, a considerable number of patients with schizophrenia are partially responsive or unresponsive to clozapine. In addition, long-term use of clozapine is associated with the development of obsessive-compulsive symptoms and metabolic syndrome. In order to overcome these short-comings and to increase efficacy, aripiprazole augmentation was implemented. Quantitative electroencephalogram will be used to monitor the occurrence of abnormal findings and to analyze the changes in electroencephalographic pattern with linear and non-linear methodology.
Comparisons: Design of double-blind randomized placebo controlled study of patients at Refractory Schizophrenia Clinique in Department of Neuropsychiatry at Seoul National University Hospital.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 61 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia |
Study Start Date : | December 2005 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | February 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: A
clozapine plus aripiprazole
|
Drug: aripiprazole
aripiprazole augmentation of clozapine
Other Names:
|
Placebo Comparator: B
clozapine plus placebo
|
Drug: placebo
placebo
|
- Brief Psychotic Rating Scale (BPRS): Measure of efficacy will be changes in BPRS total and subscale scores from baseline to 8th week endpoint. Follow-up evaluation will be made every 6th month till 1 year after 8th week end point. [ Time Frame: one year ]
- Schedule for Assessment of Negative Symptoms (SANS): Measure of efficacy will be changes in SANS total and subscale scores from baseline to 8th week endpoint. Follow-up evaluation will be made at 6 month and 12 month after 8th week end point. [ Time Frame: one year ]
- Serum Prolactin Level [ Time Frame: one year ]
- Body Mass Index & Abdominal Circumference [ Time Frame: one year ]
- Lipid Panel with LDL Cholesterol [ Time Frame: one year ]
- FBS-PP & HbA1c [ Time Frame: one year ]
- Clinical Global Impression-Severity & Improvement (CGI-S & CGI-I) [ Time Frame: one year ]
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: one year ]
- Yale-Brown Obsessive Compulsive Scale (YBOCS) [ Time Frame: one year ]
- Subjective Well-being under Neuroleptics scale (SWN) [ Time Frame: one year ]
- Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) [ Time Frame: one year ]
- Udvalg Fur Kliniske Undersogesler (UKU) [ Time Frame: one year ]
- Blood Pressure and Pulse Rate [ Time Frame: one year ]
- Admission Battery, CBC, & EKG [ Time Frame: one year ]
- Serum Clozapine Level [ Time Frame: one year ]
- Quantitative Electroencephalogram [ Time Frame: one year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female patients, 18-65 years of age.
- Patients must have a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
- Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence).
- Each patient must provide written informed consent after full explanation of study protocol, and authorized legal guardian must understand the nature of the study and must also give assent to study participation.
- Patients must have a baseline (day 0) BPRS score of at least 35 or over 2 of 5 SANS global rating item scores of at least 3.
- Patients have been receiving clozapine treatment for more than 1 year and there has been no change in clozapine dosage for more than 3 months.
- Patients must have a history of antipsychotic treatment with at least 2 different kinds prior to clozapine administration.
- Subjects who are fluent in Korean.
Exclusion Criteria:
- DSM-IV substance (except nicotine or caffeine) dependence within the past 1 year.
- Female patients who are either pregnant or lactating.
- Mental retardation (IQ < 70).
- Neurological disorders including epilepsy, stroke, or severe head trauma.
- Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, urinalysis and EKG.
- Prior history of aripiprazole non-response or intolerance.
- BPRS score of < 35 and over 4 of 5 SANS global rating item scores of < 3.
- Participation in a clinical trial of another investigational drug within 3 months (90 days) prior to study entry.
- Treatment with an injectable depot neuroleptic within less than three dosing interval between the last depot neuroleptic injections and baseline (day 0).
- History of electroconvulsive therapy within the past 3 months.
- Subjects who are not fluent in Korean.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00328367
Korea, Republic of | |
Seoul National University Hospital | |
Seoul, Korea, Republic of, 110-744 |
Principal Investigator: | Yong Sik Kim, MD, PhD | Seoul National University Hospital |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Yong Sik Kim/Professor, Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT00328367 History of Changes |
Other Study ID Numbers: |
KYS-2006-05209 |
First Posted: | May 19, 2006 Key Record Dates |
Last Update Posted: | October 29, 2008 |
Last Verified: | April 2008 |
Keywords provided by Seoul National University Hospital:
schizophrenia aripiprazole clozapine |
Additional relevant MeSH terms:
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Aripiprazole Clozapine Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants |
Physiological Effects of Drugs Psychotropic Drugs Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action GABA Antagonists GABA Agents |